{"entity":{"id":"nct05374603","kind":"trial","name":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","aka":["SOUND"],"tldr":"A phase 2 trial of Savolitinib and Durvalumab in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.","summary":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC is a phase 2 interventional study registered as NCT05374603 by AstraZeneca, with 47 participants enrolled, started 2022-11-15 and due to reach its primary completion in 2027-01-18. Interventions recorded: Savolitinib and Durvalumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05374603","url":"https://clinicaltrials.gov/study/NCT05374603"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["savolitinib","durvalumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05374603","phase":"2","setting":"Savolitinib Combine With Durvalumab in Chinese EGFR Wild-type Locally Advanced or Metastatic NSCLC Patients With MET Alteration: An Open-label, Interventional, Multiple-center, Exploratory Trial (SOUND)","sponsor":"AstraZeneca","started":"2022-11-15","startedType":"actual","enrolled":47,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05374603/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}